OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Matsen on the Effects of Decreased Breast Cancer Screening in the COVID-19 Era

January 28th 2021

Cindy B. Matsen, MD, discusses the potential effects of the decrease in screening for patients with breast cancer during the coronavirus disease 2019 pandemic.

Dr. Callander on the Expanding Role of Belantamab Mafodotin in Multiple Myeloma

January 28th 2021

Natalie S. Callander, MD, discusses the expanding role of belantamab mafodotin-blmf in multiple myeloma.

Dr. Kumar on Treatment Selection Considerations in Multiple Myeloma

January 27th 2021

Shaji K. Kumar, MD, discusses treatment selection considerations in multiple myeloma.

Dr. Fonseca on the Shift Toward Frontline Quadruplet Regimens in Multiple Myeloma

January 26th 2021

Rafael Fonseca, MD, discusses the shift toward frontline quadruplet regimens in multiple myeloma.

Dr. Ailawadhi on Potential Combination Strategies in Multiple Myeloma

January 26th 2021

Sikander Ailawadhi, MD, discusses potential combination strategies with selinexor and belantamab mafodotin-blmf in multiple myeloma.

Dr. Ohri on the Role of Chemoradiation in Locally Advanced NSCLC

January 26th 2021

Nitin Ohri, MD, discusses the role of chemoradiation therapy in locally advanced non–small cell lung cancer.

Dr. Harismendy on the Challenges Faced With Molecular Testing in DCIS

January 25th 2021

Olivier Harismendy, PhD, discusses the challenge of molecular testing in patients with ductal carcinoma in situ.

Dr. Marshall on Changes With Adjuvant Treatment in CRC

January 25th 2021

John L. Marshall, MD, discusses recent changes to the adjuvant treatment landscape in colorectal cancer.

Dr. Strickler on Dosing Regorafenib in CRC

January 25th 2021

John H. Strickler, MD, discusses dosing strategies with regorafenib in colorectal cancer.

Dr. Dasari on the Potential Clinical Implications of Fruquintinib in mCRC

January 25th 2021

Nageshwara Arvind Dasari, MD, discusses the potential clinical implications with fruquintinib in metastatic colorectal cancer.

Dr. Callander on Selecting a Frontline Treatment Strategy in Multiple Myeloma

January 22nd 2021

Natalie S. Callander, MD, discusses selecting a frontline treatment strategy for patients with multiple myeloma.

Dr. Ciombor on the FDA Approval of Trastuzumab Deruxtecan in HER2+ Metastatic Gastric Cancer

January 22nd 2021

Kristen K. Ciombor, MD, MSCI, discusses the FDA approval of fam-trastuzumab deruxtecan-nxki in HER2-positive metastatic gastric cancer.

Dr. Hubbard on Sequencing Challenges With EGFR Inhibitors in CRC

January 22nd 2021

Joleen M. Hubbard, MD, discusses sequencing challenges regarding EGFR inhibitors in colorectal cancer.

Dr. Bekaii-Saab Discusses Indicators of Progression in CRC

January 22nd 2021

Tanios S. Bekaii-Saab, MD, FACP, discusses indicators of progression in colorectal cancer.

Dr. Choueiri on the FDA Approval of Nivolumab/Cabozantinib in mRCC

January 22nd 2021

Toni K. Choueiri, MD, discusses the FDA approval of nivolumab and cabozantinib in metastatic renal cell carcinoma.

Dr. Ahn on the Growing Role of ctDNA as a Biomarker in CRC

January 21st 2021

Daniel H. Ahn, DO, discusses the growing role of circulating tumor DNA in colorectal cancer.

Dr. Halmos on the Emergence of KRAS-Targeted Therapies in Lung Cancer

January 21st 2021

Balazs Halmos, MD, MS, discusses the emergence of KRAS-targeted therapies in lung cancer.

Dr. Burris on the Potential for Novel Checkpoint Inhibitor Combinations in Oncology

January 21st 2021

Howard A. “Skip” Burris, III, MD, FASCO, FACP, discusses the potential of novel combination strategies with checkpoint inhibitors in oncology.

Dr. Lin on the Importance of Developing non-BCMA–Targeting Agents in Myeloma

January 20th 2021

Yi Lin, MD, PhD, discusses the importance of developing non-BCMA–targeting agents in multiple myeloma.

Dr. Kumar on the Emergence of MRD Negativity as an End Point in Multiple Myeloma

January 20th 2021

Shaji K. Kumar, MD, discusses the emergence of minimal residual disease negativity as a surrogate end point in relapsed/refractory multiple myeloma.